Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib continuation beyond progression in EGFR-mutant NSCLC (Phase II)
KCT0003384Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in EGFR-mutated non-small cell lung cancer, sponsored by AstraZeneca. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on KCT0003384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003384.